WALTHAM, Mass., Feb. 21, 2024 /PRNewswire/ -- Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the publication of preclinical data in Molecular Therapy that further validates the therapeutic potential of ADX-097, a tissue-targeted complement inhibitor. The paper, titled "C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement," was co-authored by Q32 Bio scientists Fei Liu, Ph.D., and Sarah Ryan, with Chief Scientific Officer Shelia Violette, Ph.D., and Stefan Wawersik, Ph.D., Vice President and Head of Research at Q32 Bio as senior authors.
SAN FRANCISCO, Calif. and BOULDER, Colo.—January 16, 2024 – Innovaccer Inc., today announced that it has acquired a 100% stake in Cured, a leading digital marketing and CRM platform for healthcare. This strategic move marks a significant milestone in Innovaccer’s commitment to revolutionize healthcare. With this transaction, Innovaccer will add over 20 health systems and digital health clients to the company’s current portfolio of over 95 customers.
NEW HAVEN, CONNECTICUT, USA, January 9, 2024 /EINPresswire.com/ -- Vita Health, the first provider of clinically validated suicide prevention through innovative care management, announced today the close of a $22.5M Series A funding round.
The funding will support the rapid expansion of life-saving services targeting youth and adults nationwide. The Vita behavioral health care pathways are based on the founding team’s successful clinical trials published in JAMA, The American Journal of Psychiatry and thousands of patient encounters demonstrating reductions in suicide attempts by more than 60% and deaths by up to 80%.
In this episode of the CU Anschutz 360 podcast, Daniel LaBarbera, PhD, director of the Center for Drug Discovery, talks about harnessing technology and innovation to speed the development of new therapies. He discusses robotic automation, quantum computing and building bridges over the ‘valley of death.’
NASHVILLE, Tenn.--(BUSINESS WIRE)--Reimagine Care, the nation’s leading provider of virtual and in-home cancer care, along with CU Innovations at the University of Colorado Anschutz Medical Campus (CU), a leading research institution committed to fostering innovation and excellence in education and healthcare, are proud to announce a poster presentation at the prestigious 2023 American Society of Hematology (ASH) Annual Meeting and Exposition.